- Home
- CAAP vs AKRO Comparison
CAAP vs AKRO Comparison
Compare CAAP & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- AKRO
- Stock Information
- Founded
- CAAP 1998
- AKRO 2017
- Country
- CAAP Luxembourg
- AKRO United States
- Employees
- CAAP N/A
- AKRO N/A
- Industry
- CAAP Aerospace
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- AKRO Health Care
- Exchange
- CAAP Nasdaq
- AKRO Nasdaq
- Market Cap
- CAAP 3.3B
- AKRO 3.9B
- IPO Year
- CAAP 2018
- AKRO 2019
- Fundamental
- Price
- CAAP $21.00
- AKRO $50.46
- Analyst Decision
- CAAP Strong Buy
- AKRO Strong Buy
- Analyst Count
- CAAP 2
- AKRO 7
- Target Price
- CAAP $24.35
- AKRO $81.57
- AVG Volume (30 Days)
- CAAP 92.3K
- AKRO 1.0M
- Earning Date
- CAAP 08-20-2025
- AKRO 08-08-2025
- Dividend Yield
- CAAP N/A
- AKRO N/A
- EPS Growth
- CAAP N/A
- AKRO N/A
- EPS
- CAAP 1.05
- AKRO N/A
- Revenue
- CAAP $1,858,038,000.00
- AKRO N/A
- Revenue This Year
- CAAP $0.91
- AKRO N/A
- Revenue Next Year
- CAAP $12.63
- AKRO N/A
- P/E Ratio
- CAAP $19.96
- AKRO N/A
- Revenue Growth
- CAAP 28.46
- AKRO N/A
- 52 Week Low
- CAAP $14.00
- AKRO $21.34
- 52 Week High
- CAAP $22.13
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CAAP 61.33
- AKRO 49.27
- Support Level
- CAAP $19.39
- AKRO $48.07
- Resistance Level
- CAAP $20.56
- AKRO $53.02
- Average True Range (ATR)
- CAAP 0.48
- AKRO 1.92
- MACD
- CAAP 0.13
- AKRO 0.11
- Stochastic Oscillator
- CAAP 99.38
- AKRO 58.03
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.